FDA要求扩大6岁以下患者使用缓释兴奋剂的减肥风险标签

The Brown University Child & Adolescent Psychopharmacology Update Pub Date : 2025-08-25 DOI:10.1002/cpu.31005

{"title":"FDA要求扩大6岁以下患者使用缓释兴奋剂的减肥风险标签","authors":"","doi":"10.1002/cpu.31005","DOIUrl":null,"url":null,"abstract":"<p>The FDA is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) — including certain formulations of amphetamine and methylphenidate — to warn about the risk of weight loss and other adverse reactions (side effects) in patients younger than 6 years taking these medications.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"27 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FDA requires expanded labeling about weight loss risk in patients younger than 6 years for extended-release stimulants\",\"authors\":\"\",\"doi\":\"10.1002/cpu.31005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The FDA is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) — including certain formulations of amphetamine and methylphenidate — to warn about the risk of weight loss and other adverse reactions (side effects) in patients younger than 6 years taking these medications.</p>\",\"PeriodicalId\":22496,\"journal\":{\"name\":\"The Brown University Child & Adolescent Psychopharmacology Update\",\"volume\":\"27 9\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Child & Adolescent Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cpu.31005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Child & Adolescent Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpu.31005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

美国食品和药物管理局正在修订所有用于治疗注意力缺陷/多动障碍（ADHD）的缓释兴奋剂的标签，包括某些安非他明和哌醋甲酯的配方，以警告6岁以下患者服用这些药物的体重减轻和其他不良反应（副作用）的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

FDA requires expanded labeling about weight loss risk in patients younger than 6 years for extended-release stimulants

The FDA is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) — including certain formulations of amphetamine and methylphenidate — to warn about the risk of weight loss and other adverse reactions (side effects) in patients younger than 6 years taking these medications.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Brown University Child & Adolescent Psychopharmacology Update

自引率

0.00%

发文量